The San Francisco Vaccine and Prevention Unit (SFVPU) provides scientific leadership, capacity to recruit study volunteers into vaccine and non-vaccine prevention trials, innovative methods for community engagement in research, and mentorship of junior investigators. We will test vaccine and prevention strategies likely to have the greatest impact in reducing HIV infection in the United States and globally through our affiliation with the HIV Vaccine Trials Network and the HIV Prevention Trials Network. The SFVPU is housed in the San Francisco Department of Public Health, using a non-profit fiscal pass-through agency, Public Health Foundation Enterprises, to provide fiscal and human-resource management.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069496-07
Application #
8415883
Study Section
Special Emphasis Panel (ZAI1-AR-A (M1))
Program Officer
Germuga, Donna E
Project Start
2007-03-02
Project End
2013-12-09
Budget Start
2013-01-01
Budget End
2013-12-09
Support Year
7
Fiscal Year
2013
Total Cost
$2,287,238
Indirect Cost
$192,769
Name
Public Health Foundation Enterprises
Department
Type
DUNS #
082199324
City
City of Industry
State
CA
Country
United States
Zip Code
91746
Wilson, Erin C; Jalil, Emilia M; Castro, Cristiane et al. (2018) Barriers and facilitators to PrEP for transwomen in Brazil. Glob Public Health :1-9
Angelidou, Konstantia; Hunt, Peter W; Landay, Alan L et al. (2018) Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy. J Infect Dis 218:239-248
Giguere, Rebecca; Rael, Christine Tagliaferri; Sheinfil, Alan et al. (2018) Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial. AIDS Behav 22:388-401
Hughes, Shana D; Sheon, Nicolas; Andrew, Erin V W et al. (2018) Body/Selves and Beyond: Men's Narratives of Sexual Behavior on PrEP. Med Anthropol 37:387-400
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Scheer, Susan; Hsu, Ling; Schwarcz, Sandra et al. (2018) Trends in the San Francisco Human Immunodeficiency Virus Epidemic in the ""Getting to Zero"" Era. Clin Infect Dis 66:1027-1034
Glidden, David V; Mulligan, Kathleen; McMahan, Vanessa et al. (2018) Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clin Infect Dis 67:411-419
Fuchs, Jonathan D; Stojanovski, Kristefer; Vittinghoff, Eric et al. (2018) A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis. AIDS Patient Care STDS 32:104-111
Ramsuran, Veron; Naranbhai, Vivek; Horowitz, Amir et al. (2018) Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. Science 359:86-90
Jalil, Emilia M; Grinsztejn, Beatriz; Velasque, Luciane et al. (2018) Awareness, Willingness, and PrEP Eligibility Among Transgender Women in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 79:445-452

Showing the most recent 10 out of 130 publications